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Clinical	Practice	Points:	
• Adrenal	cortical	carcinoma	(ACC)	is	a	rare	malignancy	with	poor	prognosis.
• The	high	rate	of	recurrence	in	this	disease	emphasizes	the	necessity	for	careful	clinical
and	radiographic	follow-up	for	timely	diagnosis	of	a	recurrence.
• Patients	with	recurrent	or	metastatic	disease	should	undergo	repeat	surgery,	if	the
tumor	is	potentially	resectable,	because	surgery	may	significantly	prolong	median
survival.
• In	this	brief	report,	a	57-year	old	male	patient	with	recurrent	and	metastatic	ACC
achieved	long	term	survival	of	11	years	with	surgery,	chemotherapy	and	mitotane.
• Whole	genome	sequencing	of	tumors	can	shed	light	on	possible	therapeutically	relevant
events	that	might	help	inform	treatment	recommendations	for	advanced	cancers.
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Introduction	
	
Adrenocortical	carcinoma	(ACC)	is	a	rare	malignancy	with	an	estimated	worldwide	annual	
incidence	of	one	to	two	per	million	[1].	It	is	responsible	for	only	approximately	0.2%	of	all	cancer	
deaths	in	the	United	States	annually,	and	it	is	the	second	most	aggressive	endocrine	malignancy	
following	anaplastic	 thyroid	cancer	 [2].	ACC	carries	a	poor	prognosis	with	an	expected	5-year	
survival	of	13%	in	patients	stage	IV	disease	[3].		Surgery	is	the	mainstay	treatment	in	localized	
ACC	 and	 creates	 the	 best	 hope	 for	 prolonged	 survival	 and	 potential	 cure.	 However,	 60%	 of	
patients	who	present	with	localized	disease	experience	recurrence	that	often	requires	systemic	
therapy	[4].		
Herein,	we	present	a	case	report	of	a	recurrent	and	metastatic	ACC	with	a	rare	discoid	
domain	 receptor-2	 (DDR2)	mutation	with	 an	 ongoing	 long-term	 survival	more	 than	 11	 years	
achieved	 with	 surgery,	 chemotherapy	 and	 mitotane	 retreatments.	 To	 date,	 only	 eight	 case	
reports,	 one	 small	 case	 series	 of	 six	 patients	 and	 12	 patients	 from	multicenter	 retrospective	
analysis	 in	 the	 literature	 have	 reported	 on	 patients	 with	 ACC	 who	 have	 achieved	 long-term	
survival	of	more	than	10	years	[5-14].	The	5-year	and	10-year	survival	of	patients	with	metastatic	
disease	 reported	 by	 Tran	 et	 al	 from	 the	multicenter	 retrospective	 analysis	was	 27%	 and	 7%,	
respectively	[14].	
	
Case	report	
	
A	57-year	old	man	presented	with	left	flank	pain	on	February	2006.	Computed	tomography	(CT)	
scan	of	the	abdomen	revealed	a	4.5	cm	left	adrenal	mass.	He	underwent	a	fine	needle	biopsy	
with	a	cytological	finding	suggestive	of	a	malignant	tumor.	A	complete	metabolic	evaluation	for	
pheochromocytoma	was	negative.	Subsequently,	he	elected	for	laparoscopic	left	adrenalectomy.	
Histological	finding	confirmed	an	adrenal	cortical	carcinoma	with	negative	margins,	no	capsule	
involvement,	 low	 to	 moderate	 mitotic	 activity	 and	 the	 presence	 of	 vascular	 invasion.	 Post-
surgical	CT	staging	examination	showed	no	evidence	of	metastatic	disease	and	the	diagnosis	of	a	
low	risk	stage	I	ACC	was	made.	The	patient	was	enrolled	into	a	routine	follow-up	with	regular	CT	
scans,	clinical	and	laboratory	examinations	for	the	first	2	years	postoperatively.	He	was	free	of	
recurrence	during	these	visits,	and	then	he	was	lost	to	follow	up	for	4	years	until	November	2012	
when	he	presented	with	symptoms	of	gross	hematuria	and	back	pain.		
Radiologic	studies	at	that	time	revealed	a	recurrent	disease	with	left	adrenal	mass	abutting	the	
left	kidney	and	spleen,	left	retroperitoneal	mass	and	left	para	spinal	soft-tissue	mass	(Figure	1A).	
In	 January	 2013,	 He	 underwent	 a	 retroperitoneal	 lymph	 node	 dissection	 and	 left	 partial	
nephrectomy	with	 pathological	 diagnosis	 of	 5.2	 cm	 recurrent	 left	 adrenal	 cortical	 carcinoma	
invading	left	kidney	and	spleen	with	positive	pancreatic	margins.	He	remained	disease	free	until	
February	2014	when	the	CT	evaluation	uncovered	several	liver	lesions	(Figure	1B).	A	liver	biopsy	
confirmed	metastatic	adrenal	cortical	carcinoma.	Subsequently,	the	patient	was	treated	with	six	
cycles	of	etoposide,	doxorubicin	and	carboplatin	(EDP),	with	concomitant	oral	mitotane	(the	dose	
titrated	according	to	serum	mitotane	levels)[15],	until	July	2014	when	the	CT	scan	revealed	no	
evidence	 of	 progression	 or	 new	 metastases.	 He	 progressed	 with	 numerous	 bilateral	 small	
pulmonary	nodules	on	CT	 images	 in	January	2015,	but	the	 liver	remained	disease-free	(Figure	
1C).		As	a	result,	he	was	reintroduced	to	a	daily	single	agent	treatment	with	mitotane,	which	he	
continues	to	take	until	present	time.	
Whole	genome	sequencing	from	the	relapsed	resected	tumor	mass,	was	performed.	The	tumor	
was	largely	devoid	of	mutations,	copy	number	alterations	or	translocations.	However,	a	discoid	
domain	 receptor-2	 (DDR2)	 missense	 mutation	 was	 discovered.	 The	 tumor	 sample’s	 exonic	
mutation	rate	was	estimated	to	be	0.5	mutations	per	megabase.	
The	patient	is	still	alive	with	radiology	studies	showing	stable	pulmonary	nodules	and	no	evidence	
of	progression	on	2.5	grams	of	daily	mitotane	alone.	His	 long-term	survival	has	reached	more	
than	11	years	at	the	last	follow	up	in	April	2017.		
	
Discussion	
ACC	 is	 a	 rare	 endocrine	malignancy.	 A	 complete	 resection	 of	 the	 primary	 tumor	 is	 the	 only	
potentially	curative	treatment. However,	even	in	patients	who	undergo	radical	adrenalectomy	
for	a	stage	I	disease,	the	recurrence	is	common	[4].	A	prognosis	of	a	metastatic	disease	is	dismal.	
The	 treatment	of	 recurrence	has	been	predominantly	based	on	chemotherapy	and	mitotane,	
although	 some	patients	may	benefit	 from	 surgical	 resection	of	 a	disease	 that	 is	 anatomically	
confined.	The	overall	survival	of	EDP	plus	Mitotane	is	about	14	months	[15].	Mitotane	is	currently	
a	 cornerstone	 in	 the	management	of	 cortisol	 secreting	ACC	 inducing	adrenal	 cortex	necrosis,	
mitochondrial	 membrane	 impairment,	 and	 irreversible	 binding	 to	 CYP	 proteins	 including	
CYP11A1,	 CYP11B1,	 CYP11B2,	 and	 3b-hydroxysteroid-dehydrogenase	 [16,	 17].	 However,	 the	
degree	 of	 response	 to	 mitotane	 is	 variable	 among	 patients	 due	 to	 the	 complexity	 of	 its	
mechanisms	 of	 action,	 pharmacokinetics	 and	 tolerability.	 The	 course	 of	 this	 patient	 was	
remarkable	 because	 he	 achieved	 an	 ongoing	 long-term	 survival	 with	 metastatic	 ACC	 after	
treatment	 with	 mitotane	 and	 chemotherapy.	 The	 finding	 of	 the	 genome	 largely	 devoid	 of	
mutations	with	the	exception	of	single	discoid	domain	receptor-2	(DDR2)	mutation	in	this	patient	
could	be	a	contributing	factor	to	his	excellent	survival	and	high	sensitivity	to	mitotane.	In	contrast	
to	our	patient,	ACC	is	generally	known	to	have	a	high	mutational	burden	[18,	19].		
DDR2	is	a	receptor	tyrosine	kinase	that	interacts	with	collagen	and	plays	a	role	in	cell	adhesion	
and	proliferation	[20].	DDR2	was	found	to	be	mutated	in	approximately	4%	of	patients	with	lung	
squamous	cell	carcinoma	[21],	lung	adenocarcinoma,	gastric	and	breast	cancer	but	not	in	ACC	
[18,	19].	Recent	report	from	pre-clinical	cell	line	and	tissue-based	model	suggests	that	somatic	
mutations	in	the	(DDR2)	are	responsive	to	dasatinib	(a	DDR2	receptor	tyrosine	kinase	inhibitor)	
[22].	Early	case	reports	have	also	reported	sensitivity	to	dasatinib	in	squamous	cell	carcinoma	of	
the	 lung	 [23].	 Based	 on	 the	 results	 from	 the	 patient	 tumor	 whole	 genome	 sequencing	 we	
hypothesize,	that	treatment	with	dasatinib	could	be	a	meaningful	approach	 in	case	of	further	
progression	of	the	disease.		
Whole	 genome	 sequencing	 can	 identify	 tumor	 drivers	 and	 potential	 actionable	 mutations,	
generally	brings	detailed	information	on	tumor	heterogeneity	and	guides	clinicians	in	decisions	
making	 for	 treatment	 recommendations	 in	 advanced	 cancers.	 We	 suggest	 whole	 genome	
sequencing	 in	 selected	 patients	 who	 have	 previously	 failed	 standard	 treatments	 and/or	 in	
patients	with	unexpected	biological	behavior	of	the	ACC.	
	
	
Conclusion	
	
This	 case	 report	 demonstrates	 an	 exceptionally	 rare	 long-term	 survival	 of	 a	 patient	 with	
metastatic	ACC.	His	 survival	 exceeding	11	 years	was	 achieved	by	 chemotherapy,	 surgery	 and	
mitotane	retreatments.	A	 rare	DDR-2	mutation	was	discovered,	 that	could	be	 illustrative	of	a	
different	biological	behavior	of	ACC	in	our	patient. 	
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Figure 1. Treatment outcome in a patient with metastatic ACC treated with 
surgery, chemotherapy and mitotane.  
  
	
Figure legend: (A) left adrenal mass abutting the left kidney and spleen before 
surgery. (B) liver metastases before chemotherapy and mitotane treatment. (C) 
No evidence of Liver metastases on follow-up Computed tomography scan.  
	
